Search

Search bills, members, committees and pages...

H.R. 3

U.S. HouseIntroduced

Summary

H.R. 3, “Reserved for the Speaker”, was introduced in the House on Jan 3, 2025 by Rep. Mike Johnson (R). It stands at Introduced.


Record

Text

H.R. 3 has no co-sponsors and has not gone to a roll call.

No text on file for H.R. 3 yet — read it at congress.gov.

Tracker

The tracker indicates the progress of this legislation as it moves through the legislative process.

Progress not harvested for this bill yet.

Reserved for the Speaker.

Sponsors

Rep. Mike Johnson (R) sponsors H.R. 3 alone.

Actions

No actions on file for H.R. 3 yet.

Votes

H.R. 3 has not gone to a roll call.

Titles

H.R. 3 goes by 2 titles.

  • Reserved for the Speaker. — Display Title
  • Reserved for the Speaker. — Official Title as Introduced

Lobbying

2 clients hired 2 firms and 8 registered lobbyists who named H.R. 3 in 8 quarterly filings, 2025 to 2026. Reported under the Lobbying Disclosure Act; a filing’s income covers everything its registrant worked that quarter, so the amounts below are the filings’, not this bill’s.

Filed under Health Issues, Budget/Appropriations.

Clients

Who paid to be heard, by how many filings named the bill.

ClientBusinessStateFirmsFilingsReported
AMGEN, INC. FKA HORIZON THERAPEUTICS USA, INC.Biopharmaceutical developmentIllinois16$360K
THE UNIVERSITY OF CHICAGO MEDICAL CENTERHealthcareIllinois12$136K

Firms

Registrants who filed on the bill, by filings.

RegistrantClientsFilingsReported
S-3 GROUP16$360K
CARMEN GROUP INCORPORATED12$136K

Lobbyists

Named on the filings that cite the bill.

Filings

The documents themselves, on the Senate’s Lobbying Disclosure site, largest reported first.

ClientRegistrantPeriodReportedDocument
THE UNIVERSITY OF CHICAGO MEDICAL CENTERCARMEN GROUP INCORPORATED2025 second_quarter$68K2nd Quarter - Report
THE UNIVERSITY OF CHICAGO MEDICAL CENTERCARMEN GROUP INCORPORATED2025 first_quarter$68K1st Quarter - Report
AMGEN, INC. FKA HORIZON THERAPEUTICS USA, INC.S-3 GROUP2026 second_quarter$60K2nd Quarter - Report
AMGEN, INC. FKA HORIZON THERAPEUTICS USA, INC.S-3 GROUP2026 first_quarter$60K1st Quarter - Report
AMGEN, INC. FKA HORIZON THERAPEUTICS USA, INC.S-3 GROUP2025 fourth_quarter$60K4th Quarter - Report
AMGEN, INC. FKA HORIZON THERAPEUTICS USA, INC.S-3 GROUP2025 third_quarter$60K3rd Quarter - Report
AMGEN, INC. FKA HORIZON THERAPEUTICS USA, INC.S-3 GROUP2025 second_quarter$60K2nd Quarter - Report
AMGEN, INC. FKA HORIZON THERAPEUTICS USA, INC.S-3 GROUP2025 first_quarter$60K1st Quarter - Report

Source: congress.gov · legiscan.com